Sandbox:patho

Revision as of 01:13, 6 October 2015 by Haytham Allaham (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
  • Neuroblastic tumors may be grouped according to International Neuroblastoma Pathology Classification (Shimada classification) into two groups: schwannian stroma rich group and a schwannian stroma poor group as illustrated below:[1][2]


 
 
 
Neuroblastic tumors
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schwannian stroma rich group
 
Schwannian stroma poor group
 
 
 
 
 
 
 
Undifferentiated neuroblastoma
Poorly differentiated neuroblastoma
Differentiating neuroblastoma
 
Nodular ganglioneuroblastoma
Intermixed ganglioneuroblastoma
Maturing ganglioneuroma
Mature ganglioneuroma
 
 
 
 
 
 


  • Based on the degree of the cellular maturity and composition, neuroblastoma may be further classified into three subtypes according to the International Neuroblastoma Pathology Classification which include:[1]
  • Undifferentiated neruoblastoma
  • Poorly differentiated neuroblastoma
  • Differentiating neuroblastoma
  • The table below summarizes the differnces between the three histological subtypes of neurublastoma:
Risk Factor Description
Undifferentiated neruoblastoma Completely formed by neuroblasts with no maturity of ganglion cells
Poorly differentiated neuroblastoma Mostly formed by neuroblasts with less the 5% maturing ganglion cells
Differentiating neuroblastoma

Predominantly formed by neuroblasts but with more than 5% mature ganglion cells

  1. 1.0 1.1 Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma. Stanford Medicine Surgical Pathology Criteria(2015) http://surgpathcriteria.stanford.edu/srbc/neuroblastoma-ganglioneuroblastoma-ganglioneuroma/ Accessed on October, 5 2015
  2. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S; et al. (2001). "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (9): 2451–61. PMID 11745303.